LOXO Oncology Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • LOXO Oncology's estimated annual revenue is currently $248M per year.(i)
  • LOXO Oncology received $294.8M in venture funding in June 2017.
  • LOXO Oncology's estimated revenue per employee is $321,600
  • LOXO Oncology's total funding is $506M.

Employee Data

  • LOXO Oncology has 771 Employees.(i)
  • LOXO Oncology grew their employee count by 38% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Loxo Oncology is a biopharmaceutical company dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on treatments aimed at cancers caused by a single inappropriate DNA change, known as oncogenic drivers, which the tumor depends on for growth and survival. Loxo Oncology develops purpose-built medicines designed to selectively and potently inhibit these oncogenic drivers. We believe that this approach, combined with the use of tumor genomic testing to identify appropriate patients, will allow us to develop medicines that provide best-in-class disease control and safety and, ultimately, deliver on the promise of precision medicine. We are based in Stamford, CT with sites in San Francisco, CA and Boulder, CO. For more information about Loxo Oncology, please visit us at www.loxooncology.com.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





LOXO Oncology News

2022-04-20 - Eli Lilly and Company's (LLY) CEO Dave Ricks on Q1 2022 Results - Earnings Call Transcript

Jake Van Naarden - Chief Executive Officer, Loxo Oncology, Lilly and President, Lilly Oncology. Mike Mason - President, Lilly Diabetes.

2022-04-17 - NeoGenomics Inc. Announces Partnership with Lilly for Lung ...

... testing services and global oncology contract research services, ... Biomarkers and Diagnostics Development, Loxo Oncology at Lilly.

2022-04-06 - New mutations may have implications for BTK inhibitor use in ...

... had undergone treatment with pirtobrutinib (LOXO-305; Eli Lilly, Loxo Oncology), a noncovalent Bruton tyrosine kinase (BTK) inhibitor.

2021-10-07 - Eli Lilly and : Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EORTC Virtual Interna ...

2019-09-08 - Biopharma Pushes for Wider Acceptance, Use and ...

One example is the drug Vitrakvi, developed by Eli Lilly and its Loxo Oncology, which is marketed by Bayer. Vitrakvi works on cancers where ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

LOXO Oncology Funding

DateAmountRoundLead InvestorsReference
2014-05-07$24.0MBNew Enterprise AssociatesArticle
2017-06-22$294.8MUndisclosedMorgan StanleyArticle